Morfit G Mason

Director Morfit buys 96,000 CRM shares at $260.58 ($25.0M) after recent sales, expanding holdings to 2,994,509 shares

Morfit purchased 96,000 shares at $260.58 on 2025-12-05, increasing his holdings by 3.3% to 2,994,509 shares. This buy follows three consecutive sales in mid-December 2024 at $259.53 (within 1 cent of today's price), a pattern that warrants attention: his prior trades at CRM show a 4-of-4 success rate at the 90-day mark, including 100% well-timed sells. The current stock price of $259.53 sits 29.4% below the 52-week high of $367.87, though the 30-day trend is positive at +8.2%. The company fundamentals remain solid with $10.3B in quarterly revenue and an 8.7% annual growth rate, though the P/E of 33.66 reflects elevated market expectations. The timing and scale of this purchase—after a deliberate exit sequence just weeks prior—merit close observation.

Director G Mason Morfit sells 1,015,800 shares over 3 days (Dec 18–20) for $349,993,962.99; post-sale holdings 2,898,509 shares (-26.0% reduction)

Morfit executed three separate open-market sales totaling 1,015,800 shares (1.02M shares) for $349,993,962.99 across December 18–20, 2024, reducing his holdings from 3,914,309 shares to 2,898,509 shares, a -26.0% reduction. The blended average transaction price of $344.55 sits just 0.3% above the current price of $343.65 and within the 52-week range; the stock has risen 5.5% in the past 30 days and 28.8% over 90 days. His prior buy transaction at CRM on 2024-06-03 produced a +11.9% gain at 30 days and +8.5% at 90 days, and his cross-ticker track record shows 1 prior buy with a 100.00% 90-day win rate. The magnitude and timing of this multi-day liquidation—following a strong 90-day rally—merit observation for any emerging context around valuation, strategic repositioning, or changes in Morfit's conviction at this holding.